The role of biologically active substances in gastroesophageal reflux disease in patients with type 2 diabetes mellitus

Ye.S. Sirchak, O.O. Boldizhar, M.P. Stan


Background. The factors influencing the progression and clinical manifestations of gastroesophageal reflux di­sease (GERD) in patients with type 2 diabetes mellitus (DM) have not been sufficiently studied so far. To investigate the features of changes in serum prostaglandin (Pg) І2 and F2α levels depending on the clinical course of GERD in patients with type 2 DM was the purpose of our work. Materials and methods. The study involved 82 patients with GERD and type 2 DM (main, group 1) and comparison group (85 individuals, group 2). Serum levels of prostaglandin PgF2α and 6-keto-prostaglandin F1α (blood prostacyclin — PgI2) were evaluated in patients. Results. Digestive complaints characteristic of GERD have been detected in 61.0 % of persons from group 1, 22.0 % of individuals with combined pathology have been diagnosed with otolaryngologic form of GERD, and 17.1 % had a cardiac form. Patients with combined pathology have a more significant increase in the concentration of PgI2 with extra-esophageal manifestations of GERD, especially with its otolaryngologic form (4.1 times higher than indicators of the control group), whereas in patients with cardiac mask of GERD, its concentration is increased 3.5-fold, and in those with esophageal manifestations of GERD and type 2 DM — 3-fold. In patients with GERD, similar changes were detected 2.4 times (otolaryngologic manifestations), 2.2 times (cardiac manifestations) and 1.6 times (typical manifestations of GERD) more often. Conclusions. GERD in patients with type 2 DM is often manifested by extravascular symptoms (otolaryngologic, cardiac form). The maximum increase in the level of serum prostacyclin is established in patients with extraesophageal manifestations of GERD and type 2 DM, especially with its otolaryngologic form.


gastroesophageal reflux disease; clinical forms of gastroesophageal reflux disease; prostaglandins; type 2 diabetes mellitus


Pankiv VI. Diabetes mellitus: definition, classification, epidemiology, risk factors. Mìžnarodnij endokrinologìčnij žurnal.2013;(55):95-104. (in Ukrainian).

Tkach SM. Diagnosis and treatment of acid-related diseases in patients with diabetes mellitus. Clinical Endocrinology and Endocrine Surgery. 2017;(59):21-27. (in Russian).

Kon’kova LA, Kon’kov AV. Gastroesophageal reflux: extra-oesophageal manifestations. Medicinskij vestnik MVD. 2016;81(2):247-250. (in Russian).

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. doi: 10.1038/ajg.2012.444.

Sviridova TN, Alekseev NJu, Kozlov JuS, authors; Minakov JeV, editor. Gastrojezofageal'naja refljuksnaja bolezn': metodicheskie ukazanija [Gastroesophageal reflux disease: guidelines]. Voronezh; 2009. 69 p. (in Russian).

Stepanov IuM, Zakharash MP, Skrypnik IN, et al. The newest technologies in theoretical and practical gastroenterology. Zdorov’ja Ukrai'ny. 2016;(386-387):20-21. (in Russian).

Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensu. Gut. 2018 Feb 3;pii:gutjnl-2017-314722. doi: 10.1136/gutjnl-2017-314722.

Promberger R, Lenglinger J, Riedl O, et al. Gastro-oesophageal reflux disease in type 2 diabetics: symptom load and pathophysiologic aspects - a retro-pro study. BMC Gastroenterol. 2013 Aug 23;13:132. doi: 10.1186/1471-230X-13-132.

Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal reflux disease in type II diabetes mellitus with or without peripheral neuropathy. J Neurogastroenterol Motil. 2011 Jul;17(3):274-8. doi: 10.5056/jnm.2011.17.3.274.

Robleto DO, Herman CA. Cardiovascular effects of prostaglandin I2 and prostaglandin F2 alpha in the unanesthetized bullfrog, Rana catesbeiana. J Exp Zool. 1988 Apr;246(1):10-6. doi: 10.1002/jez.1402460103.

Takeuchi K, Nagahama K. Animal model of acid-reflux esophagitis: pathogenic roles of acid/pepsin, prostaglandins, and amino acids. Biomed Res Int. 2014;2014:532594. doi: 10.1155/2014/532594.

Burduli NM, Tadtaeva DIa. The influence of intravenous laser therapy on prostaglandin E2 and F2-alpha dynamics and the state of microcirculation in the patients presenting with gastroesophageal reflux disease. Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul'tury. 2012; 89(6):17–20. (in Russian).

Copyright (c) 2018 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта